It appeared that Gilead Sciences, Inc. (NASDAQ:GILD) had turned the corner earlier this year after a long slump. Just three years ago, Gilead reached a high of $120 per share at the height of its HCV treatment sales surge. Then its revenues …
April 25 (Reuters) - Jubilant Life Sciences Ltd: * CO, JUBILANT STOCK HOLDING, OTHERS FILED APPEALS …
AbbVie Inc. (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are two of the world's biggest biotech stocks. However, their sales have been heading in different directions and each has offered up very different forecasts for 2018. Given that …
The S&P/TSX Composite Index progressed 39.11 points, or 0.25%, to close Friday's trading session at 15,577.81. The …
Owning a stock that doubles in value in less than 11 months is exciting. But what word do you use for a stock that rises to 4.5 times its original price in that amount of time? Thrilling? Exhilarating? Whatever word is the best fit, it applies to …
AbbVie Inc. (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are two of the world's biggest biotech stocks. However, their sales have been heading in different directions and each has offered up very different forecasts for 2018. Given that …
In May, Andrew Left of Citron Research blasted Exact Sciences (NASDAQ: EXAS), calling the stock "a poster child for what goes wrong when Wall Street gets a hold of a healthcare concept with no discrimination for whether it's good or …